By combining online academics with clinical simulation, a nationwide initiative is removing bottlenecks in radiologic ...

Three Distinct Pathways to Pharm.D. Degree LECOM’s School of Pharmacy offers three fully accredited Pharm.D. pathways, each ...

Microbial infections, caused by bacteria, viruses, and parasites, pose a significant challenge to global health, affecting millions annually. Despite advancements in medical science, understanding the ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly monitoring for potential threats. In the skin's outermost layer, the epidermis, ...

Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...

TULSA, Okla. — Pathways Adult Learning Center broke ground on a new facility that will help the organization expand their services for adults with intellectual and developmental disabilities (I/DD).

A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...

A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...